🚀 VC round data is live in beta, check it out!
Wockhardt Valuation Multiples
Discover revenue and EBITDA valuation multiples for Wockhardt and similar public comparables like Pfizer India, Ultragenyx, Nektar Therapeutics, Bavarian Nordic and more.
Wockhardt Overview
About Wockhardt
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The group is involved in new drug discovery, contract manufacturing, API, vaccines, and branded pharmaceuticals business. In addition, it operates a chain of super-specialty hospitals. Its novel antibiotic platform has various assets, such as Zaynich (WCK 5222); Miqnaf (Nafithromycin), a macrolide-class respiratory antibiotic; Ertapenem-Zidebactam (WCK 6777); Foviscu (WCK 2482), an antibiotic for Gram-negative infections; and Odrate (WCK 6777), among others. The group is mainly engaged in the pharmaceutical business, which is considered its only reportable business segment. Geographically, it generates maximum revenue from Europe, followed by India, the USA, and the Rest of the world.
Founded
1999
HQ
Employees
2.3K
Website
Sectors
Financials (FY)
EV
$3B
Wockhardt Financials
Wockhardt reported last fiscal year revenue of $313M and EBITDA of $48M.
In the same fiscal year, Wockhardt generated $192M in gross profit, $48M in EBITDA, and had net loss of ($5M).
Revenue (LTM)
Wockhardt P&L
In the most recent fiscal year, Wockhardt reported revenue of $313M and EBITDA of $48M.
Wockhardt expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $313M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $192M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 61% | XXX | XXX | XXX |
| EBITDA | — | XXX | $48M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 15% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 6% | XXX | XXX | XXX |
| Net Profit | — | XXX | ($5M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (2%) | XXX | XXX | XXX |
| Net Debt | — | — | $188M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Wockhardt Stock Performance
Wockhardt has current market cap of $2B, and enterprise value of $3B.
Market Cap Evolution
Wockhardt's stock price is $15.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $2B | 3.1% | XXX | XXX | XXX | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialWockhardt Valuation Multiples
Wockhardt trades at 8.3x EV/Revenue multiple, and 53.6x EV/EBITDA.
EV / Revenue (LTM)
Wockhardt Financial Valuation Multiples
As of April 19, 2026, Wockhardt has market cap of $2B and EV of $3B.
Equity research analysts estimate Wockhardt's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Wockhardt has a P/E ratio of (482.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 8.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 53.6x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 134.3x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 13.6x | XXX | XXX | XXX |
| P/E | — | XXX | (482.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (62.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Wockhardt Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Wockhardt Margins & Growth Rates
Wockhardt's revenue in the last fiscal year grew by 1%.
Wockhardt's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Wockhardt Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 25% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 55% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Wockhardt Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Wockhardt | XXX | XXX | XXX | XXX | XXX | XXX |
| Pfizer India | XXX | XXX | XXX | XXX | XXX | XXX |
| Ultragenyx | XXX | XXX | XXX | XXX | XXX | XXX |
| Nektar Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Bavarian Nordic | XXX | XXX | XXX | XXX | XXX | XXX |
| Anhui Anke Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Wockhardt M&A Activity
Wockhardt acquired XXX companies to date.
Last acquisition by Wockhardt was on XXXXXXXX, XXXXX. Wockhardt acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Wockhardt
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialWockhardt Investment Activity
Wockhardt invested in XXX companies to date.
Wockhardt made its latest investment on XXXXXXXX, XXXXX. Wockhardt invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Wockhardt
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Wockhardt
| When was Wockhardt founded? | Wockhardt was founded in 1999. |
| Where is Wockhardt headquartered? | Wockhardt is headquartered in India. |
| How many employees does Wockhardt have? | As of today, Wockhardt has over 2K employees. |
| Is Wockhardt publicly listed? | Yes, Wockhardt is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Wockhardt? | Wockhardt trades under WOCKPHARMA ticker. |
| When did Wockhardt go public? | Wockhardt went public in 2000. |
| Who are competitors of Wockhardt? | Wockhardt main competitors are Pfizer India, Ultragenyx, Nektar Therapeutics, Bavarian Nordic. |
| What is the current market cap of Wockhardt? | Wockhardt's current market cap is $2B. |
| What is the current revenue of Wockhardt? | Wockhardt's last fiscal year revenue is $313M. |
| What is the current EV/Revenue multiple of Wockhardt? | Current revenue multiple of Wockhardt is 8.3x. |
| Is Wockhardt profitable? | No, Wockhardt is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.